Zevra Therapeutics, Inc. (ZVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.40-1.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZVRA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | 136.1 | 106.5 | 23.6 | 27.5 | 10.2 | 28.7 | 13.3 | 12.8 | — | — | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Cost of Revenues | — | — | — | 2.9 | 0.2 | 2.1 | — | 10.0 | — | — | — | — |
| Operating Expenses & Income | ||||||||||||
| Selling, General & Admin | 74.6 | 77.6 | 54.9 | 34.3 | 15.0 | — | — | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — | 10.2 | 8.8 | 19.4 | 41.8 | 20.6 | 20.5 | 13.9 |
| Operating Income | 82.4 | (62.9) | (87.0) | (49.6) | (42.6) | 7.7 | (5.6) | (20.3) | (55.9) | (33.4) | (37.5) | (22.8) |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | — | 8.0 | 7.4 | 1.5 | 0.3 | 0.2 | 4.8 | 4.9 | 5.5 | 5.8 | 5.5 | 2.7 |
| Other Non-Operating Income / Expenses | (13.1) | 149.6 | (3.1) | 3.6 | 15.8 | (16.3) | (7.2) | (4.2) | (0.7) | (10.1) | 21.0 | (31.8) |
| Asset Writedown | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | 69.3 | 86.7 | (90.1) | (46.0) | (26.8) | (8.5) | (12.8) | (24.5) | (56.6) | (43.4) | (16.5) | (54.6) |
| Income Tax Expense | 11.0 | 3.4 | 15.4 | 0.0 | (0.0) | 0.0 | (0.0) | (0.0) | (0.1) | (0.0) | (0.0) | 0.0 |
| Net Income | ||||||||||||
| Net Income | 58.3 | 83.2 | (105.5) | (46.0) | (26.8) | (8.6) | (12.8) | (24.5) | (56.5) | (43.4) | (16.5) | (54.7) |
| Per Share | ||||||||||||
| Basic EPS | 0.98 | 1.40 | (2.28) | (1.30) | (0.78) | (2.11) | (3.21) | — | — | — | — | — |
| Diluted EPS | 0.95 | 1.35 | — | — | — | (2.11) | (3.21) | — | — | — | — | — |
| Revenue per Share | 2.22 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 59.2 | 55.3 | 46.3 | 35.5 | 34.5 | 29.8 | 4.0 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 61.3 | 57.3 | — | — | — | 29.8 | 4.0 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | (58.9) | (80.6) | (48.6) | (41.6) | 8.0 | (5.3) | (20.0) | (55.6) | (33.0) | (37.3) | (22.7) |
| EBIT | 82.4 | (62.9) | (87.0) | (49.6) | (42.6) | 7.7 | (5.6) | (20.3) | (55.9) | (33.4) | (37.5) | (22.8) |
| Effective Tax Rate | 15.9% | — | — | 0.0% | 0.1% | -0.4% | 0.3% | 0.1% | 0.2% | 0.1% | 0.1% | -0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.